Objectives: Complete responses have been observed in NPM1-mutated AML patients with dactinomycin, a nucleolar stress-inducing drug. Here, we report a single-center experience of compassionate use of dactinomycin in untreated or relapsed/ refractory NPM1-mutated AML.

Methods: From September 2015 to February 2019, 26 adult patients with NPM1-mutated AML received dactinomycin in different situations: front-line treatment in 4 unfit patients (16%); morphologic (n = 16, 62%), molecular relapses (n = 4, 16%), refractory disease (n = 1, 13%), or postremission therapy in second complete response (n = 1, 13%).

Results: Median age was 62.5 years. Median number of dactinomycin cycle was 1 (1-8), and 7 patients (27%) received more than 3 cycles. Three out of 17 patients (18%) in morphologic relapse or refractory to chemotherapy achieved complete remission after the first cycle of dactinomycin. None of the 4 patients unfit for intensive chemotherapy responded to dactinomycin as front-line therapy. Grade 3-4 adverse events were thrombocytopenia (n = 11, 42%), neutropenia (n = 11, 42%), GI toxicity (n = 6, 23%), mucositis (n = 5, 19%), lung infection (n = 5, 19%), and skin rash (n = 2, 7.6%).

Conclusions: Dactinomycin is an inexpensive and easily available drug that may induce significant responses in few AML patients with NPM1 mutations with an acceptable safety profile.

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13438DOI Listing

Publication Analysis

Top Keywords

dactinomycin
8
npm1 mutations
8
npm1-mutated aml
8
aml patients
8
n = 11 42%
8
n = 5 19%
8
patients
7
dactinomycin acute
4
acute myeloid
4
myeloid leukemia
4

Similar Publications

Background: Rhabdomyosarcoma and other soft tissue sarcomas (STS) with high-risk features are still associated with an unsatisfactory outcome. We evaluated the efficacy of oral maintenance therapy added at the end of standard therapy in patients with high-risk rhabdomyosarcoma and STS.

Methods: CWS-2007-HR was a multicentre, open-label, randomised controlled, phase 3 trial done at 87 centers in 5 countries.

View Article and Find Full Text PDF

The metastasis or recurrence of rhabdomyosarcoma (RMS) is the primary cause of tumour-related deaths. Patients with high-risk RMS have poor prognosis with a 5-year overall survival rate of 20-30%. The lack of specific drug-targeted therapy and chemotherapy resistance are the main reasons for treatment failure.

View Article and Find Full Text PDF

TREATMENT OUTCOMES OF GESTATIONAL TROPHOBLASTIC DISEASE, EXPERIENCE FROM SAUDI ARABIA.

J Ayub Med Coll Abbottabad

November 2024

Department of Medical Oncology, Prince Sultan Military Medical City, Riyadh-Saudi Arabia.

Article Synopsis
View Article and Find Full Text PDF

This report explores a noteworthy case diagnosed with primary pulmonary choriocarcinoma (PPC), a rare and often fatal non-seminomatous germ cell tumor. Initially misdiagnosed as lung adenocarcinoma, this case underscores the diagnostic complexities associated with PPC. A 44-year-old woman initially misdiagnosed with non-small lung cancer underwent unsuccessful chemoradiation.

View Article and Find Full Text PDF
Article Synopsis
  • - Choriocarcinoma is a highly aggressive but treatable form of gestational trophoblastic neoplasm, which can lead to severe health issues, including massive hemorrhage and death, particularly in women of childbearing age with high-risk scores.
  • - A case study highlights a 20-year-old woman with widespread metastatic choriocarcinoma who lapsed in treatment due to the COVID-19 pandemic, resulting in severe complications like intraabdominal hemorrhage that required immediate surgery.
  • - Despite being in a coma and on a ventilator, the patient successfully underwent multiagent chemotherapy, initially with the EMA/CO regimen followed by the TP/TE regimen, leading to a significant decrease in her β-hCG levels,
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!